MARKET

RVMD

RVMD

Revolution Medicines, Inc.
NASDAQ
207.68
+1.04
+0.50%
Pre Market: 209.35 +1.67 +0.80% 08:52 10/06 EDT
OPEN
207.68
PREV CLOSE
206.64
HIGH
210.27
LOW
201.83
VOLUME
3.29K
TURNOVER
0
52 WEEK HIGH
224.31
52 WEEK LOW
45.80
MARKET CAP
44.51B
P/E (TTM)
-23.5070
1D
5D
1M
3M
1Y
5Y
1D
Maintained Buy on Revolution Medicines: Strong RAS Franchise Momentum and ESMO GI 2026 Data Support Unchanged $315 Price Target
TipRanks · 1d ago
Revolution Medicines begins treating patients in RASolute 309 trial
TipRanks · 1d ago
Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC
Benzinga · 1d ago
Weekly Report: what happened at RVMD last week (0928-1002)?
Weekly Report · 1d ago
Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold
Seeking Alpha · 3d ago
Revolution Medicines (RVMD) Could Be 8% Overvalued As FTSE All World Inclusion Draws Focus
Simply Wall St · 3d ago
Revolution Medicines participates in a conference call with JPMorgan
TipRanks · 4d ago
Does Rasonque Launch Change The Bull Case For Revolution Medicines Stock?
Simply Wall St · 09/29 17:12
More
About RVMD
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.

Webull offers Revolution Medicines Inc stock information, including NASDAQ: RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVMD stock methods without spending real money on the virtual paper trading platform.